Supplementary protection
LT - Vakcina prieš HPV16 ir HPV18 ir mažiausiai vieną kitą HVP tipą, parinktą iš HVP 31, 45 arba 52
EN - VACCINE AGAINST HPV16 AND HPV18 AND AT LEAST ANOTHER HPV TYPE SELECTED FROM HPV 31, 45 OR 52
SPC
| (11) |
Number of the document |
C 1758609-1 |
| (68) |
Number of the document |
1758609
|
| (21) |
Application number for Supplementary Protection Certificate |
PA 2015 045 |
| (22) |
Date of filing the application |
2015-12-07 |
| (41) |
Date of publication of the application |
2016-01-11 |
|
Date of publication of SPC |
2017-05-10 |
| (24) |
Date of coming into effect of SPC |
2025-06-15 |
Applicant
| (71) |
GlaxoSmithKline Biologicals SA,
Rue de l`Institut 89, 1330 Rixensart,
BE
|
Grantee
| (73) |
GlaxoSmithKline Biologicals SA,
Rue de l`Institut 89, 1330 Rixensart,
BE
|
Attorney or representative
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
Number, date and code of the country of origin of the first authorization to place the medicinal or plant protection product on the market within regional economic community
| (93) |
EU/1/15/1007/001, EU/1/15/1007/002, EU/1/15/1007/003, 2015-06-12
|
Calculated date of expiry of the SPC
| (94) |
2030-06-12 |
Name of the product protected by the basic patent
| (95) |
HPV L1 VLPs 16 + 18 + 31 |
Paediatric extension
|
Request filed |
SPC extension granted until |
Request refused |
|
2022-12-02 |
2030-12-12 |
|
Last renewal fee
|
Payment date |
Validity (years) |
Amount |
|
2025-04-14 |
1 |
347.00
EUR
|
Next renewal fee
|
2026-06-15 |
Legal status
|
SPC term extension granted
|
|
